- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04927065
A Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 (COVID-19) Variants
A Phase 2/3 Study to Evaluate the Immunogenicity and Safety of mRNA Vaccine Boosters for SARS-CoV-2 Variants
Study Overview
Status
Conditions
Detailed Description
This clinical study will consist of 9 parts: A (1 and 2), B, C, D, E, F, G, H, and J.
Part A.1 will evaluate 2 dose levels of the mRNA-1273.211 vaccine when administered as a single booster dose to adult participants of the mRNA-1273-P301 (COVE [NCT04470427]) study who have previously received 2 doses of mRNA-1273.
Part A.2 will evaluate the immunogenicity, safety, and reactogenicity of the mRNA-1273.214 vaccine candidate when administered as a second booster dose to adult participants of the mRNA-1273-P205 study who have previously received 2 doses of mRNA-1273 as a primary series and a first booster of (50 μg total mRNA content) of the mRNA-1273.211 in Part A.1 of this study.
Part B will evaluate the mRNA-1273 vaccine when administered as a single booster dose to adult participants of the mRNA-1273-P301 (COVE [NCT04470427]) study who have previously received 2 doses of mRNA-1273.
Part C will evaluate 2 dose levels of the mRNA-1273.617.2 vaccine when administered as a single booster dose to adult participants of the mRNA-1273-P301 (COVE [NCT04470427]) study who have previously received 2 doses of mRNA-1273.
Part D will evaluate 2 dose levels of the mRNA-1273.213 vaccine when administered as a single booster dose to adult participants of the mRNA-1273-P301 (COVE [NCT04470427]) study who have previously received 2 doses of mRNA-1273.
Part E will be enrolled at a single clinical study site. Part E will evaluate the mRNA-1273.213 vaccine when administered as a single booster dose to adult participants who have previously received 2 doses of any SARS-CoV-2 mRNA authorized vaccine, including mRNA-1273.
Part F will consist of 2 cohorts: Cohort 1 will consist of adults who have previously received 2 doses of mRNA-1273 as primary series. Cohort 1 will evaluate the mRNA-1273.529 vaccine as a single booster dose. Cohort 2 will consist of adults who have previously received 2 doses of mRNA-1273 as a primary series and a single booster dose of mRNA-1273 in study mRNA-1273-P301 (COVE [NCT04470427]) or under the emergency use authorization (EUA). Cohort 2 will evaluate the mRNA-1273.529 and mRNA-1273 vaccines as a single booster dose.
Part G will evaluate the mRNA1273.214 vaccine candidate when administered as a second booster dose to adults who have previously received 2 doses of mRNA-1273 as a primary series and a single booster dose of mRNA-1273.
Part H will evaluate the immunogenicity, safety, and reactogenicity of the mRNA- 1273.222 vaccine candidate when administered as a second booster dose to adults who have previously received 2 doses of mRNA-1273 as a primary series and a single booster dose of mRNA-1273.
Part J will evaluate mRNA-1273.815 and mRNA-1273.231 when administered as a booster dose to adults who previously received a primary series of mRNA vaccine, a first booster dose of a monovalent mRNA vaccine, and a second booster dose of a bivalent mRNA vaccine against SARS-COV-2.
Study Type
Enrollment (Actual)
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
California
-
Sacramento, California, United States, 95864
- Benchmark Research (California)
-
-
Florida
-
Hollywood, Florida, United States, 33024
- Research Centers of America
-
Jacksonville, Florida, United States, 32216
- Jacksonville Center for Clinical Research
-
-
Georgia
-
Savannah, Georgia, United States, 31406
- Meridian Clinical Research-(Savannah Georgia)
-
-
Iowa
-
Sioux City, Iowa, United States, 51106
- Meridian Clinical Research (Iowa)
-
-
Kansas
-
Lenexa, Kansas, United States, 66219
- Johnson County Clinical Trials
-
-
Louisiana
-
Baton Rouge, Louisiana, United States, 70809
- Meridian Clinical Research-(Baton Rouge, Louisiana)
-
Metairie, Louisiana, United States, 70006
- Benchmark Research
-
-
Maryland
-
Rockville, Maryland, United States, 20854
- Meridian Clinical Research-(Rockville Maryland)
-
-
Massachusetts
-
Boston, Massachusetts, United States, 02115
- Brigham and Women's Hospital
-
-
Missouri
-
Saint Louis, Missouri, United States, 63141
- Sundance Clinical Research
-
Saint Louis, Missouri, United States, 63110
- Washington State University
-
-
Nebraska
-
Grand Island, Nebraska, United States, 68803
- Meridian Clinical Research (Grand Island, Nebraska)
-
Norfolk, Nebraska, United States, 68701
- Meridian Clinical Research (Norfolk-Nebraska)
-
Omaha, Nebraska, United States, 68134
- Meridian Clinical Research-(Omaha Nebraska)
-
-
New York
-
New York, New York, United States, 13901
- Meridian Clinical Research, LLC
-
-
North Carolina
-
Wilmington, North Carolina, United States, 28403
- Trial Management Associates
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States, 73112
- Lynn Health Science Institute
-
-
Texas
-
Austin, Texas, United States, 78745
- Tekton Research, Inc.
-
Austin, Texas, United States, 78705
- Benchmark Research - Austin - HyperCore
-
Fort Worth, Texas, United States, 76135
- Benchmark Research - Fort Worth - HyperCore
-
Houston, Texas, United States, 77081
- Texas Center for Drug Development, Inc.
-
Tomball, Texas, United States, 77375
- DM Clinical Research
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- For female participants of childbearing potential: negative pregnancy test, adequate contraception or has abstained from all activities that could result in pregnancy for at least 28 days prior to Day 1, agreement to continue adequate contraception or abstinence through 3 months following the vaccination, and not currently breastfeeding.
- Participants must have been either previously enrolled in the mRNA-1273-P301 (COVE) study, must have received 2 doses of mRNA-1273 in that study, with their second dose at least 6 months prior to enrollment in this study (mRNA-1273-P205), and must be currently enrolled and compliant in that study (that is, has not withdrawn or discontinued early); or participant must have received 2 doses of mRNA-1273 under the EUA with their second dose at least 6 months prior to enrollment in mRNA-1273-P205; or have received a 2 dose primary series of mRNA-1273 followed by a 50 μg booster dose of mRNA-1273 in the mRNA-1273-P301 (COVE) study or under EUA at least 3 months prior to enrolment in mRNA-1273-P205; and able to provide proof of vaccination status at the time of screening (Day 1); or for enrollment in Part A.2, participant must be currently enrolled and compliant in Part A.1 of the mRNA 1273 P205 study and must have received their first booster dose of mRNA 1273.211 50 μg; or for enrollment in Part J, participant must meet at least 1 of the following criteria: completed enrollment in Part H of the mRNA-1273-P205 study; or received a 2-dose primary series of mRNA-1273 (100 μg) followed by a 50 μg booster dose of mRNA-1273 in the mRNA-1273-P301 (COVE) study or under EUA, followed by a 50 μg booster dose of mRNA-1273.222 under EUA at least 3 months prior to enrollment in Part J of mRNA-1273-P205; or previously received a 2-dose primary series of mRNA vaccine against SARS-CoV-2 followed by a booster dose of a monovalent mRNA vaccine, followed by a second booster dose of a bivalent mRNA vaccine. Participants in Part J must also provide proof of vaccination status at the time of screening (Day 0 or Day 1).
Key Exclusion Criteria:
- Significant exposure to someone with SARS-CoV-2 infection or COVID-19 in the past 14 days, as defined by the US Centers for Disease Control and Prevention (CDC) as a close contact of someone who has had COVID-19.
- Known history of SARS-CoV-2 infection within 3 months prior to enrollment.
- Is acutely ill or febrile (temperature ≥38.0°Celsius/[100.4°Fahrenheit]) less than 72 hours prior to or at the Screening Visit (Day 0) or Day 1.
- Has a medical, psychiatric, or occupational condition that may pose additional risk as a result of participation, or that could interfere with safety assessments or interpretation of results according to the investigator's judgment.
- Has received systemic immunosuppressants or immune-modifying drugs for >14 days in total within 6 months prior to Screening (for corticosteroids ≥10 milligrams (mg)/day of prednisone equivalent) or is anticipating the need for immunosuppressive treatment at any time during participation in the study.
- Known or suspected allergy or history of anaphylaxis, urticaria, or other significant AR to the vaccine or its excipients.
- Has a documented history of myocarditis or pericarditis within 2 months prior to Screening Visit (Day 0).
- Has received or plans to receive any licensed vaccine ≤28 days prior to the injection (Day 1) or a licensed vaccine within 28 days before or after they study injection, with the exception of influenza vaccines, which may be given 14 days before or after receipt of a study vaccine.
- Has received systemic immunoglobulins or blood products within 3 months prior to the Screening Visit (Day 0) or plans for receipt during the study.
- Has donated ≥450 milliliters (mL) of blood products within 28 days prior to the Screening Visit (Day 0) or plans to donate blood products during the study.
- Is currently experiencing an SAE in Study mRNA-1273-P301 (COVE) at the time of screening for this study.
Note: Other inclusion and exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Prevention
- Allocation: Non-Randomized
- Interventional Model: Sequential Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Part A.1: mRNA-1273.211 50 μg
Participants will receive 1 intramuscular booster dose of 50 micrograms (μg) of mRNA-1273.211
on Day 1.
|
Sterile liquid for injection
|
Experimental: Part A.1: mRNA-1273.211 100 μg
Participants will receive 1 intramuscular booster dose of 100 μg of mRNA-1273.211
on Day 1.
|
Sterile liquid for injection
|
Experimental: Part B: mRNA-1273 100 μg
Participants will receive 1 intramuscular booster dose of 100 μg of mRNA-1273 on Day 1.
|
Sterile liquid for injection
|
Experimental: Part C: mRNA-1273.617.2 100 μg
Participants will receive 1 intramuscular booster dose of 100 μg of mRNA-1273.617.2 on Day 1.
|
Sterile liquid for injection
|
Experimental: Part C: mRNA-1273.617.2 50 μg
Participants will receive 1 intramuscular booster dose of 50 μg of mRNA-1273.617.2 on Day 1.
|
Sterile liquid for injection
|
Experimental: Part D: mRNA-1273.213 50 μg
Participants will receive 1 intramuscular booster dose of 50 μg of mRNA-1273.213
on Day 1.
|
Sterile liquid for injection
|
Experimental: Part D: mRNA-1273.213 100 μg
Participants will receive 1 intramuscular booster dose of 100 μg of mRNA-1273.213
on Day 1.
|
Sterile liquid for injection
|
Experimental: Part E: mRNA-1273.213 100 μg
Participants will receive 1 intramuscular booster dose of 100 μg of mRNA-1273.213
on Day 1.
|
Sterile liquid for injection
|
Experimental: Part F Cohort 1: mRNA-1273.529 50 μg
Participants will receive 1 intramuscular first booster dose of 50 μg of mRNA-1273.529
on Day 1.
|
Sterile liquid for injection
|
Experimental: Part G: mRNA-1273.214 50 μg
Participants will receive 1 intramuscular second booster dose of mRNA-1273.214
50 μg on Day 1.
|
Sterile liquid for injection
|
Experimental: Part A.2: mRNA-1273.214 50 μg
Participants will receive 1 intramuscular booster dose of 50 μg of mRNA-1273.214
on Day 1.
|
Sterile liquid for injection
|
Experimental: Part H: mRNA-1273.222 50 μg
Participants will receive 1 intramuscular second booster dose of 50 μg of mRNA-1273.222
on Day 1.
|
Sterile liquid for injection
|
Experimental: Part F Cohort 2: mRNA-1273.529 50 μg and mRNA-1273 50 μg
Participants will receive 1 intramuscular second booster dose of 50 μg of mRNA-1273.529
or mRNA-1273 enrolled sequentially (after receiving a primary series of mRNA-1273 and a single booster dose of mRNA-1273 50 μg) on Day 1.
|
Sterile liquid for injection
Sterile liquid for injection
|
Experimental: Part J: mRNA-1273.815 or mRNA-1273.231
Participants will receive 1 intramuscular booster dose of 50 μg of mRNA-1273.815
or 50 ug of mRNA-1273.231
on Day 1.
|
Sterile liquid for injection
Sterile liquid for injection
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Geometric Mean Titer (GMT) of Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2)-Specific Antibody at Day 29
Time Frame: Day 29
|
Day 29
|
GMT of SARS-CoV-2-Specific Antibody at Day 91 (For Part G only)
Time Frame: Day 91
|
Day 91
|
GMT of Omicron-Specific Antibody at Day 91 (For Part G only)
Time Frame: Day 91
|
Day 91
|
Seroresponse Rate of Vaccine Recipients at Day 29
Time Frame: Day 29
|
Day 29
|
Seroresponse Rate of Vaccine Recipients at Day 91 (For Part G only)
Time Frame: Day 91
|
Day 91
|
Number of Participants with Solicited Local and Systemic Reactogenicity Adverse Reactions (ARs)
Time Frame: Up to Day 7 (7 days post-vaccination)
|
Up to Day 7 (7 days post-vaccination)
|
Number of Participants with Unsolicited Adverse Events (AEs)
Time Frame: Up to Day 28 (28 days post-vaccination)
|
Up to Day 28 (28 days post-vaccination)
|
Number of Participants with Serious AEs (SAEs), Medically Attended AEs (MAAEs), AEs Leading to Withdrawal, and AEs of Special Interest (AESIs)
Time Frame: Up to Day 366
|
Up to Day 366
|
GMT of Omicron-Specific Antibody (For Part J only) at Day 15
Time Frame: Day 15
|
Day 15
|
GMT of Omicron-Specific Antibody (For Parts F, G, H and J only) at Day 29
Time Frame: Day 29
|
Day 29
|
Geometric mean fold rise (GMFR) of Omicron-Specific Antibody (For Part J only) at Day 15
Time Frame: Day 15
|
Day 15
|
Seroresponse Rate of Vaccine Recipients at Day 15 (For Part J only)
Time Frame: Day 15
|
Day 15
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
GMT of SARS-CoV-2-Specific Antibody
Time Frame: Days 1, 15, 181, and 366
|
Days 1, 15, 181, and 366
|
Seroresponse Rate of Vaccine Recipients
Time Frame: Days 1, 15, 181, and 366
|
Days 1, 15, 181, and 366
|
Collaborators and Investigators
Sponsor
Publications and helpful links
General Publications
- Chalkias S, Harper C, Vrbicky K, Walsh SR, Essink B, Brosz A, McGhee N, Tomassini JE, Chen X, Chang Y, Sutherland A, Montefiori DC, Girard B, Edwards DK, Feng J, Zhou H, Baden LR, Miller JM, Das R. A Bivalent Omicron-Containing Booster Vaccine against Covid-19. N Engl J Med. 2022 Oct 6;387(14):1279-1291. doi: 10.1056/NEJMoa2208343. Epub 2022 Sep 16.
- Chalkias S, Schwartz H, Nestorova B, Feng J, Chang Y, Zhou H, Dutko FJ, Edwards DK, Montefiori D, Pajon R, Leav B, Miller JM, Das R. Safety and Immunogenicity of a 100 mug mRNA-1273 Vaccine Booster for Severe Acute Respiratory Syndrome Coronavirus-2 (SARS-CoV-2). medRxiv. 2022 Mar 7:2022.03.04.22271830. doi: 10.1101/2022.03.04.22271830. Preprint.
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Estimated)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- mRNA-1273-P205
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on SARS-CoV-2
-
Argorna Pharmaceuticals Co., LTDCompleted
-
Argorna Pharmaceuticals Co., LTDCompleted
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.Active, not recruiting
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological...Active, not recruiting
-
Arcturus Therapeutics, Inc.Terminated
-
University Hospital Inselspital, BerneUniversity of Bern; Lucerne University of Applied Sciences and ArtsCompleted
-
Centre Hospitalier Universitaire DijonUnknown
-
AIM Vaccine Co., Ltd.Zhejiang Provincial Center for Disease Control and PreventionNot yet recruiting
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical College; Ningbo Rongan Biological...Not yet recruiting
-
AIM Vaccine Co., Ltd.First Affiliated Hospital Bengbu Medical CollegeActive, not recruiting
Clinical Trials on mRNA-1273.214
-
ModernaTX, Inc.Completed
-
ModernaTX, Inc.RecruitingSARS-CoV-2United States, Puerto Rico
-
ModernaTX, Inc.CompletedInfluenza | SARS-CoV-2 | RSVUnited Kingdom, Australia, United States
-
ModernaTX, Inc.Completed
-
ModernaTX, Inc.Active, not recruitingRespiratory Syncytial VirusUnited States
-
ModernaTX, Inc.Recruiting
-
Sheba Medical CenterModernaTX, Inc.CompletedCOVID-19 | SARS CoV 2 Infection | COVID-19 Pandemic | ImmunogenicityIsrael
-
Murdoch Childrens Research InstituteCoalition for Epidemic Preparedness Innovations; The Peter Doherty Institute...Active, not recruiting
-
Murdoch Childrens Research InstituteCoalition for Epidemic Preparedness Innovations; The Peter Doherty Institute...Withdrawn
-
ModernaTX, Inc.Active, not recruitingA Study of mRNA-based Influenza and SARS-CoV-2 (COVID-19) Multi-component Vaccines in Healthy AdultsInfluenza | SARS-CoV-2United States